ALLO-501, an anti-CD19 allogeneic CAR T-cell therapy, shows promise among relapsed/refractory non-Hodgkin lymphoma patients, according to initial findings presented at the ASCO 2020 Annual Meeting (Abstract 8002).
Wolters Kluwer (“we” or “us”) wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain…
An abstract is unavailable.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
An abstract is unavailable.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Answer each quiz question to better understand the patient’s journey and determine the correct diagnosis. Wolters Kluwer (“we” or “us”) wants to inform you about…
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
